共 50 条
Serum phytanic and pristanic acid levels and prostate cancer risk in Finnish smokers
被引:10
|作者:
Wright, Margaret E.
[1
,2
]
Albanes, Demetrius
[3
]
Moser, Ann B.
[4
]
Weinstein, Stephanie J.
[3
]
Snyder, Kirk
[5
]
Mannisto, Satu
[6
]
Gann, Peter H.
[1
]
机构:
[1] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60612 USA
[2] Amer Acad Pediat, Elk Grove Village, IL 60007 USA
[3] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA
[4] Kennedy Krieger Inst, Baltimore, MD USA
[5] Informat Management Serv Inc, Silver Spring, MD USA
[6] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland
来源:
CANCER MEDICINE
|
2014年
/
3卷
/
06期
关键词:
Biomarker;
diet;
phytanic acid;
pristanic acid;
prostate cancer;
METHYLACYL-COA RACEMASE;
PROSPECTIVE COHORT;
BETA-CAROTENE;
FATTY-ACID;
DISEASE;
PLASMA;
METAANALYSIS;
CONSUMPTION;
METABOLISM;
BIOMARKERS;
D O I:
10.1002/cam4.319
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Phytanic acid is a saturated branched-chain fatty acid found predominantly in red meat and dairy products, and may contribute to the elevated risks of prostate cancer associated with higher consumption of these foods. Pristanic acid is formed during peroxisomal oxidation of phytanic acid, and is the direct substrate of a-Methyl-CoA-Racemase (AMACR)-an enzyme that is consistently overexpressed in prostate tumors relative to benign tissue. We measured phytanic and pristanic acids as percentages of total fatty acids by gas chromatography-mass spectrometry in prediagnostic blood samples from 300 prostate cancer cases and 300 matched controls, all of whom were participants in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study supplementation trial and follow-up cohort. In addition to providing a fasting blood sample at baseline, all men completed extensive diet, lifestyle, and medical history questionnaires. Among controls, the strongest dietary correlates of serum phytanic and pristanic acids were saturated fat, dairy fat, and butter (r = 0.50 and 0.40, 0.46 and 0.38, and 0.40 and 0.37, respectively; all P-values <0.001). There was no association between serum phytanic acid and risk of total or aggressive prostate cancer in multivariate logistic regression models (for increasing quartiles, odds ratios (OR) and 95% confidence intervals (CI) for aggressive cancer were 1.0 (referent), 1.62 (0.97-2.68), 1.12 (0.66-1.90), and 1.14 (0.67-1.94), P-trend = 0.87). Pristanic acid was strongly correlated with phytanic acid levels (r = 0.73, P < 0.0001), and was similarly unrelated to prostate cancer risk. Significant interactions between phytanic and pristanic acids and baseline circulating beta-carotene concentrations were noted in relation to total and aggressive disease among participants who did not receive beta-carotene supplements as part of the original ATBC intervention trial. In summary, we observed no overall association between serum phytanic and pristanic acid levels and prostate cancer risk. Findings indicating that the direction and magnitude of these associations depended upon serum levels of the antioxidant beta-carotene among men not taking beta-carotene supplements should be interpreted cautiously, as they are likely due to chance.
引用
收藏
页码:1562 / 1569
页数:8
相关论文